BioInsights - Toward an integrated model of product characterization for CAR-T cell therapy drug development efforts
Positive CHMP opinion for Novartis blood cancer drug | Science|Business
Ibrutinib potentiates CTL019 cell expansion and engraftment, which... | Download Scientific Diagram
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
Building blocks for institutional preparation of CTL019 delivery - Cytotherapy
Novartis' CTL019 Applied for Clinical Trial in China to Officially Enter the Chinese Market |_Pharmasources.com
Relationship between exposure and expansion of CTL019 cells and... | Download Scientific Diagram
Recent updates on CAR T clinical trials for multiple myeloma | Molecular Cancer | Full Text
The FDA Approves the First CAR-T Cell Therapy for Cancer
Frontiers | The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice | Immunology
What's happening under the hood: The cellular kinetics of a CAR T cell therapy
ODAC greenlights Novartis' CAR-T cell therapy CTL019 - European Biotechnology
ELIANA: CTL019 in R/R ALL - Leukemias - 2016 Hematology Meeting - Oncology - Clinical Care Options
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
CAR-T cell therapy CTL019 gets FDA breakthrough therapy status | Pharma Intelligence
Molecular structure of chimeric antigen receptor used for CTL019.... | Download Scientific Diagram
CAR T-Cell Therapy For Multiple Myeloma: Promising Signs Of Efficacy (ASCO 2015)
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 - Cytotherapy
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia | NEJM
Primary analysis results from Novartis pivotal JULIET trial show Kymriah™
CTL019 for Leukemia, Lymphoid Clinical Trial | Power
Frontiers | Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward | Immunology
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B | DDDT
Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma - Makita - 2017 - Cancer Science - Wiley Online Library
